Targeting this part of the pathway in conjunction with canonical inhibitors like BSO may be an exciting avenue of therapy for MYCN-amplified NB, and advances our understanding of how MYCN meets the enhanced GSH reliance in MYCN-amplified neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.